Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty-five analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and twenty have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $312.30.

A number of research analysts recently weighed in on the company. Canaccord Genuity Group raised their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday. Sanford C. Bernstein reduced their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $280.00 to $328.00 in a research note on Monday.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,234 shares of company stock worth $19,958,097. Corporate insiders own 1.50% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ALNY. Victory Capital Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 10.9% in the third quarter. Victory Capital Management Inc. now owns 42,909 shares of the biopharmaceutical company's stock valued at $11,801,000 after acquiring an additional 4,229 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Alnylam Pharmaceuticals by 11.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 1,906 shares of the biopharmaceutical company's stock worth $524,000 after purchasing an additional 190 shares during the period. OneDigital Investment Advisors LLC purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $281,000. CIBC Asset Management Inc grew its holdings in Alnylam Pharmaceuticals by 5.5% during the 3rd quarter. CIBC Asset Management Inc now owns 4,483 shares of the biopharmaceutical company's stock valued at $1,233,000 after buying an additional 234 shares in the last quarter. Finally, Empowered Funds LLC raised its position in shares of Alnylam Pharmaceuticals by 315.0% during the third quarter. Empowered Funds LLC now owns 7,064 shares of the biopharmaceutical company's stock valued at $1,943,000 after buying an additional 5,362 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Down 3.4 %

Shares of ALNY stock traded down $9.74 during mid-day trading on Friday, reaching $280.96. 1,065,379 shares of the company's stock traded hands, compared to its average volume of 806,012. The company's 50-day moving average price is $257.81 and its 200-day moving average price is $260.02. The company has a market cap of $36.37 billion, a P/E ratio of -129.47 and a beta of 0.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.